Articles

Elderly patients with HER2-positive advanced breast cancer demonstrated shorter chemotherapy durations, poorer overall survival, and increased rates of adverse events, emphasizing the need for prospective studies to improve outcomes. Read More ›

This real-world study of community-based oncology clinics demonstrates that patients receive variable treatment patterns in later line settings, and there is no clear management strategy being utilized. With recently approved targeted therapies for HER2-positive metastatic breast cancer, improvements in patient outcomes are slowly being seen. Read More ›

A phase 2 trial of Enhertu (trastuzumab deruxtecan) in patients with HER2-positive metastatic breast cancer show high rates of positive results in patients who have been heavily pretreated. These results are preliminary and encouraging. Read More ›

Identified subpopulations of patients showed the largest absolute advances in 6-year invasive disease-free survival for pertuzumab compared with placebo. Read More ›

Breast cancer and its treatment impacts sexual health, which is an important topic for patients and clinicians to be able to address throughout the treatment process. Read More ›

Treatment-related amenorrhea with a standard combination chemotherapy regimen occurred at a rate that was nearly double that observed with trastuzumab emtansine plus pertuzumab, implying that gonadal function may be preserved through an antibody–drug conjugate regimen. Read More ›

The DESTINY-Breast05 trial will help researchers understand the potential benefit of Enhertu (trastuzumab deruxtecan), a powerful potential treatment of patients with breast cancer with residual invasive disease after receiving chemotherapy. Read More ›

An increase in neoadjuvant therapy use has paralleled shifts in the standard anti-HER2 therapies; however, neoadjuvant patients are primarily treated with dual HER2 blockade and chemotherapy, with a taxane-based regimen preference. Read More ›

Panelists discuss the challenges of the pandemic and its impact on the risk for pandemic-related disruptions in cancer care, breast cancer diagnosis, timing and choice of treatment, and mental health. Read More ›

De-escalation of adjuvant cytotoxic chemotherapy among patients who experienced pathologic complete response in early-stage HER2-positive breast cancer appears to be an acceptable approach for both patients and physicians. Read More ›